ROCKVILLE, MD, UNITED STATES, March 20, 2025 /EINPresswire / -- According to a recently updated industry report released by Fact, the global phenylketonuria treatment market is expected to reach ...

BioMarin has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary ...

BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically ...

PR Newswire SAN RAFAEL, Calif., April 2, 2025 Company plans to submit for regulatory approval later this year SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceut ...

evaluating the potential meaningful benefits of sepiapterin treatment in phenylketonuria or PKU patients. Sepiapterin has a dual mechanism of action to increase activity of the phenylalanine ...

San Rafael, California Thursday, April 3, 2025, 18:00 Hrs [IST] ...

Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging ...

Relief’s 2024 Annual Report, which includes pipeline and portfolio updates, corporate governance and compensation disclosures, and financial statements, is available on the Company’s website.

Detailed study results will be presented at an upcoming medical meeting and submitted to health authorities later this year to expand Palynziq’s label to include adolescents.

Learn more about whether Moderna, Inc. or Roivant Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.